Medherant has been awarded a grant by Innovate UK to help it upscale production of its TEPI Patch drug delivery system for clinical trials.
TEPI Patch technology enables the development of drug-in-adhesive patch products “with better adhesion and more efficient delivery of drugs through the skin over a prolonged period,” according to the firm.
Medherant's first product, an Ibuprofen TEPI Patch, is currently being assessed in Phase I clinical development with initial results expected in later this year.
The firm said it recently installed its own pilot-scale patch manufacturing plant and has successfully produced non-GMP patches of the Ibuprofen TEPI Patch, as well as TEPI Patches for third parties intending to evaluate the suitability of the technology for their own medicines.
The £52,000 grant from Innovate will enable the firm to buy equipment and move forward with its plans to extend its pilot scale manufacture of patches formulated with TEPI Patch technology to GMP manufacture for clinical trials.